Organization | Swansea University

Swansea University Report issue

Academic/Hospital Phase 3 Phase 4

Founded: Swansea United Kingdom (1920)

Organization Overview

First Clinical Trial

2006

NCT00346827

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Swansea Bay University Health Board | Swansea Hospital, Swansea, Wales | Swansea NHS Trust | Swansea Trials Unit, Swansea University Medical School, Swansea, UK. | Swansea University | Swansea University, Swansea, United Kingdom, SA2 8PP

Active Ingredients

Drugs in Phase 4 Trials (2)

folic acid (1 trial)

l-epigallocatechin (1 trial)

Drugs in Phase 3 Trials (3)

apomorphine (apokyn) (1 trial)

gentamicin (garamycin) (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

Drugs in Other Trials (12)

bovine colostrum (1 trial)

capsaicin (qutenza) (1 trial)

fish oil (Omegavan) (1 trial)

glucose (1 trial)

insulin lispro (humalog) (1 trial)

isomaltulose (1 trial)

maltodextrin (1 trial)

multivitamins (1 trial)

sitagliptin (januvia) (1 trial)

sodium chloride (1 trial)

sucrose (1 trial)

water (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Depression (Phase 4)

Depressive Disorder (Phase 4)

Malnutrition (Phase 3)

Parkinson Disease (Phase 3)

Severe Acute Malnutrition (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 12
# of Trial APIs: 17